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Abstract
Background: This study compares inflammation-related biomarkers with established cardiometabolic risk factors in the
prediction of incident type 2 diabetes and incident coronary events in a prospective case-cohort study within the
population-based MONICA/KORA Augsburg cohort.
Methods and Findings: Analyses for type 2 diabetes are based on 436 individuals with and 1410 individuals without
incident diabetes. Analyses for coronary events are based on 314 individuals with and 1659 individuals without incident
coronary events. Mean follow-up times were almost 11 years. Areas under the receiver-operating characteristic curve (AUC),
changes in Akaike’s information criterion (DAIC), integrated discrimination improvement (IDI) and net reclassification index
(NRI) were calculated for different models. A basic model consisting of age, sex and survey predicted type 2 diabetes with an
AUC of 0.690. Addition of 13 inflammation-related biomarkers (CRP, IL-6, IL-18, MIF, MCP-1/CCL2, IL-8/CXCL8, IP-10/CXCL10,
adiponectin, leptin, RANTES/CCL5, TGF-b1, sE-selectin, sICAM-1; all measured in nonfasting serum) increased the AUC to
0.801, whereas addition of cardiometabolic risk factors (BMI, systolic blood pressure, ratio total/HDL-cholesterol, smoking,
alcohol, physical activity, parental diabetes) increased the AUC to 0.803 (DAUC [95% CI] 0.111 [0.092–0.149] and 0.113
[0.093–0.149], respectively, compared to the basic model). The combination of all inflammation-related biomarkers and
cardiometabolic risk factors yielded a further increase in AUC to 0.847 (DAUC [95% CI] 0.044 [0.028–0.066] compared to the
cardiometabolic risk model). Corresponding AUCs for incident coronary events were 0.807, 0.825 (DAUC [95% CI] 0.018
[0.013–0.038] compared to the basic model), 0.845 (DAUC [95% CI] 0.038 [0.028–0.059] compared to the basic model) and
0.851 (DAUC [95% CI] 0.006 [0.003–0.021] compared to the cardiometabolic risk model), respectively.
Conclusions: Inclusion of multiple inflammation-related biomarkers into a basic model and into a model including
cardiometabolic risk factors significantly improved the prediction of type 2 diabetes and coronary events, although the
improvement was less pronounced for the latter endpoint.
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Introduction
Based on data from observational and intervention studies,
subclinical inflammation is considered a risk factor for the
development of type 2 diabetes [1–3]. In many prospective
studies, circulating concentrations of acute-phase proteins, cyto-
kines, chemokines and soluble adhesion molecules are associated
with incident type 2 diabetes [1,4]. However, the association of
each of these biomarkers alone with incident disease is rather
weak, because hazard ratios (HRs) for 1-SD increases of single
biomarkers are usually ,2 and mostly even ,1.5 [5]. Statistical
simulations indicate that higher HRs or the combination of
multiple biomarkers with low HRs are needed for better prediction
[6,7]. Despite the wealth of data on individual inflammation-
related biomarkers and incident type 2 diabetes, the predictive
value of combinations of multiple of these biomarkers is still
unclear [4].
Simple immune scores based on five or six markers of
subclinical inflammation in the ARIC (Atherosclerosis Risk In
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Communities) and MONICA/KORA (MONItoring of trends and
determinants in CArdiovascular disease/Cooperative Health
Research in the Region of Augsburg) Augsburg cohorts showed
that the risk for type 2 diabetes was almost 4-fold increased in
individuals with high compared to those with low circulating levels
of all tested immune markers after adjustment for multiple
confounders [8,9]. These initial data indicated that the strength
of association between subclinical inflammation and incident type
2 diabetes could be increased by a combination of several
inflammation-related biomarkers. However, both studies did not
report areas under the receiver-operating characteristic curves
(AUC) or C-statistics to assess the relevance of these biomarkers
for the prediction of type 2 diabetes or to compare them with
established cardiometabolic risk factors.
Two recent reports from the Inter99 and FINRISK97 cohorts
provided some evidence that risk scores from multiple biomarkers
may indeed improve the prediction of type 2 diabetes over and
above certain established risk factors [5,10]. Both studies included
measurements of a large range of inflammation-related biomark-
ers. However, cardiometabolic and inflammation-related bio-
markers were combined with the aim to derive final risk scores
based on only a few biomarkers for diabetes prediction, whereas
the question how cardiometabolic and inflammation-related
biomarkers compare has not been addressed. Moreover, both
studies had in common that they were based on biomarker
measurements from fasting blood samples. As circulating concen-
trations of several immune mediators respond to food intake and/
or display circadian rhythms [11,12], it is as yet unknown whether
measurements of inflammation-related biomarkers from nonfast-
ing blood samples can also be used for modeling the risk of type 2
diabetes.
In order to characterize the relevance of markers of subclinical
inflammation for the prediction of physician-diagnosed type 2
diabetes, we addressed the following questions in the population-
based MONICA/KORA cohort: (i) What is the accuracy of
models based on inflammation-related biomarkers in the predic-
tion of incident type 2 diabetes? (ii) Is this accuracy comparable
with established cardiometabolic risk factors? (iii) Can the
accuracy be improved by combining both sets of risk factors? (iv)
How does the accuracy of prediction of incident diabetes compare
with that of coronary events using the same set of biomarkers and
risk factors in the same population?
Materials and Methods
Study Design and Population
The design of this prospective case-cohort study within the
population-based MONICA/KORA Augsburg cohort has been
described in detail before [9,13,14]. Briefly, three independent
cross-sectional population-based surveys were performed within
the MONICA Augsburg project in 1984/85 (S1), 1989/90 (S2)
and 1994/95 (S3) in Augsburg and two adjacent counties
(Germany). The total number of participants was 13,427 (6,725
men, 6,702 women) aged 25–64 (S1) or 25–74 years (S2, S3). All
subjects were prospectively followed within the KORA research
frame. The studies were approved by the local authorities and
performed according to the Declaration of Helsinki. The case-
cohort study was approved by the Bayerische Landesärztekam-
mer. All participants provided written informed consent.
The incidence of type 2 diabetes between participants’ study
start dates and December 31st, 2002 was assessed using a written
follow-up questionnaire sent to all participants of the 3 baseline
surveys in 1997/1998 and 2002/2003. Furthermore, all S1
participants were invited to a follow-up examination in 1987/
1988. Cases with self-reported incident diabetes were validated by
a questionnaire mailed to the treating physician or medical chart
review [13]. Only subjects for whom the treating physician clearly
reported a diagnosis of type 2 diabetes or for whom a diagnosis of
type 2 diabetes was mentioned in the medical records or who were
taking antidiabetic medication were classified as cases for the
present analysis. Measurements of autoantibodies to exclude type
1 diabetes were not performed in the study.
Details on the selection of study participants are shown in the
supporting information (Fig. S1). This study was based on 1,846
participants (244 men, 192 women with incident type 2 diabetes;
693 men, 717 women without incident type 2 diabetes) with
complete information on all biomarkers and cardiometabolic risk
factors and no prevalent diabetes. Mean follow-up time (6 SD)
was 10.664.6 years (range 1.0–18.2 years).
Incident coronary events were defined as combined endpoint of
incident non-fatal myocardial infarction and fatal coronary death
or sudden cardiac death before the age of 75 years. Cases were
identified through the MONICA/KORA Augsburg coronary
event registry and follow-up questionnaires for persons who had
moved out of the study area. Until December 2000, a major non-
fatal myocardial infarction was diagnosed based on the MONICA
algorithm (symptoms, cardiac enzymes, ECG changes). Since
January 2001 myocardial infarction was diagnosed according to
criteria defined by the European Society of Cardiology and the
American College of Cardiology [15,16]. Coronary deaths were
validated by autopsy reports, death certificates, chart review and
information from the last treating physician.
Details on the selection of study participants are shown in the
supporting information (Fig. S2). This study was based on 1,973
participants (239 men, 75 women with incident coronary events;
793 men, 866 women without incident coronary events) with
complete information on all biomarkers and cardiometabolic risk
factors and no prevalent myocardial infarction. Mean follow-up
time (6 SD) was 10.564.5 years (range 0.05–18.2 years).
Assessment of Cardiometabolic and Inflammation-
Related Risk Factors
Information on sociodemographic and lifestyle variables as well
as on parental history of diabetes and myocardial infarction was
collected through standardized interviews. In addition, standard-
ized medical examinations including collection of a nonfasting
venous blood sample were performed. All procedures and
laboratory methods for cardiometabolic risk factors have been
described in detail [9,13,14,17,18].
Laboratory methods for the assessment of inflammation-related
biomarkers have been reported before [9,13,14,19–22]. Table S1
(supporting information) provides an overview of assays, reagents
and coefficients of variation (CVs) for the measurement of serum
concentrations of C-reactive protein (CRP); interleukin-6 (IL-6);
IL-18; macrophage-migration inhibitory factor (MIF); monocyte
chemoattractant protein-1 (MCP-1)/C-C motif ligand 2 (CCL2);
IL-8/C-X-C motif ligand 8 (CXCL8); interferon-c-inducible
protein-10 (IP-10)/CXCL10; adiponectin; leptin; regulated on
activation, normal T-cell expressed and secreted (RANTES)/
CCL5; transforming growth factor-b1 (TGF-b1); soluble E-
selectin (sE-selectin); and soluble intercellular adhesion molecule-
1 (sICAM-1).
Statistical Analysis
Descriptive analyses for baseline characteristics were carried out
for cases and non-cases for both outcomes. For continuous
variables, means with SD were determined using the SAS
procedure SURVEYMEANS and were compared with t tests
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using SURVEYREG. In case of non-normality, log-transformed
variables were used, and results were presented as geometric
means with antilogs of SEs of the adjusted log-means. For
categorical variables cases and non-cases were compared using
Wald chi-square test using SURVEYFREQ. Weighting was
performed using the survey- and sex-specific sampling weights.
Correlations between inflammation-related biomarkers were
assessed by Spearman correlation coefficients (r).
To assess the impact of inflammation-related biomarkers and
cardiometabolic risk factors on incident type 2 diabetes or
coronary events, Cox proportional hazards regression was applied
by calculating a first model for each biomarker which included the
respective biomarker and age, sex and survey as adjustments
(model 1) and a second model which included additionally the
categorical variables smoking status (never/former/current smok-
er), alcohol consumption (no/moderate/high consumption),
physical activity (low/high), family history of diabetes for incident
type 2 diabetes or family history of myocardial infarction for
incident coronary events (positive/negative/unknown), and prev-
alent diabetes for incident coronary events (yes/no), as well as the
continuous variables systolic blood pressure, ratio of total
cholesterol to HDL cholesterol and BMI as adjustments (model
2). Additional models were calculated by reducing or extending
the number of covariables as indicated. For the Cox regression,
each biomarker concentration was included standardized by
subtracting the mean and divided by the SD of the biomarker
concentration [(biomarker – mean(biomarker))/SD(biomarker)].
This standardization (also known as z transformation) allows a
comparison of the associations of each biomarker as it is
independent from the underlying unit and distribution. Based on
the Cox regression, HRs with 95% confidence intervals (95% CI)
and P values were calculated. For all analyses, P,0.05 was
considered to be statistically significant.
The accuracy of the different models to assess 10-year event risk
were estimated by four measures: (i) the area under the receiver-
operating characteristic curve (AUC) (also known as C-statistic or
C-index) using survival probabilities within 10 years estimated by
a modified Kaplan-Meier method to account for censored
observations and the weighting scheme appropriate to the case-
cohort design; AUC differences between two models are given as
DAUC [23]; (ii) Akaike’s information criterion (AIC) regarding an
AIC difference (DAIC) between two models of .10 essentially
different (the lower the AIC, the better the fit of the model)
[24,25]; (iii) the integrated discrimination improvement (IDI)
statistics which can be viewed as the difference of the R2 statistic
between two models, i.e. the difference in the proportion of
variance explained by the two models [26,27]; and (iv) the net
reclassification index (NRI) using the categories 0–3.0%, 3.1–
8.0%, 8.1–15.0% and .15% [26,27]. Sensitivity analyses were
performed using lower (0–2.0%, 2.1–5.0%, 5.1–10.0% and
.10%) and higher (0–5.0%, 5.1–10.0%, 10.1–20.0% and
.20%) thresholds for both outcomes. 95% CI for DAUC and
IDI were calculated using a bootstrap percentile approach
following Efron and Tibshirani [28]. The bootstrap sampling
was conducted accounting for the case-cohort design. All statistical
evaluations were performed using the SAS software package
(Version 9.1, SAS-Institute, Cary, NC, USA).
Results
Study Populations
Table S2 gives the baseline characteristics of the overlapping
study populations with/without incident type 2 diabetes as well as
with/without coronary events during the follow-up period. Slightly
larger populations with fewer exclusions due to incomplete
biomarker data have been described before [13,29]. Briefly, cases
for both outcomes were older, more likely to be male, had a higher
BMI, a less favorable metabolic profile and higher levels for most
inflammation-related biomarkers. A correlation matrix for the
inflammation-related biomarkers is given in the supporting
information (Table S3).
Modeling the Risk of Type 2 Diabetes
Fig. 1 shows HRs (95% CI) for increases of inflammation-
related biomarkers standardized by z-transformation for incident
type 2 diabetes. In the model adjusted for age, sex, survey and
cardiometabolic risk factors (model 2), IL-18, adiponectin, sE-
selectin and sICAM-1 were each significantly associated with
incident type 2 diabetes with HRs betwen 1.11 and 1.67 (0.33 for
the protective adipokine adiponectin).
AUCs were calculated for different sets of risk factors for
incident type 2 diabetes (Table 1). Age, sex and survey (model a)
predicted type 2 diabetes with an AUC of 0.690 (the AUC for age
alone was 0.670). Addition of all 13 inflammation-related
biomarkers (model b) significantly increased the AUC to 0.801
(DAUC [95% CI] 0.111 [0.092–0.149] compared to model a;
P,0.05). Similarly, addition of cardiometabolic risk factors (BMI,
systolic blood pressure, ratio of total cholesterol/HDL cholesterol,
smoking, alcohol, physical activity, parental history of diabetes;
model c) significantly improved the AUC to 0.803 (DAUC [95%
CI] 0.113 [0.093–0.149] compared to model a; P,0.05). When all
13 biomarkers were added to model c, the combination of age, sex,
survey, inflammation-related biomarkers and cardiometabolic risk
factors (model d) led to an AUC of 0.847 (DAUC [95% CI] 0.044
[0.028–0.066] compared to model c, P,0.05). The differences in
DAUC, AIC as well as data for IDI and NRI (Table 1, Table S4)
indicate that addition of all 13 inflammation-related biomarkers to
the basic model a or to the cardiometabolic risk model c improved
the models substantially.
Measures for DAUC, DAIC, IDI and NRI also revealed that
adiponectin and E-selectin were the biomarkers which improved
model fit the most when added to model c. Moreover, a model
that only included the four biomarkers that were significantly
associated with incident diabetes (Fig. 1) was almost as good as
model d based on all 13 biomarkers (Table 1, Table S4).
Modeling the Risk of Coronary Events
As shown in Fig. 2, two inflammation-related biomarkers were
significantly associated with the risk for coronary events in the fully
adjusted models (HRs for IL-6 and sICAM-1: 1.23 and 1.31,
respectively).
Analogous analyses for coronary events as described above
yielded AUCs of 0.745 for age alone, 0.807 for model a (age, sex,
survey), 0.825 for model b (addition of inflammation-related
biomarkers to model a, DAUC [95% CI] 0.018 [0.013–0.038],
P,0.05), 0.845 for model c (addition of cardiometabolic risk
factors to model a, DAUC [95% CI] 0.038 [0.028–0.059],
P,0.05) and 0.851 for model d (combination of all biomarkers
and risk factors, DAUC [95% CI] 0.006 [0.003–0.021], P,0.05
compared with model c). The differences in DAUC, IDI and NRI
(Table 2, Table S5) indicated that addition of all 13 inflammation-
related biomarkers significantly improved the basic model a and
the cardiometabolic risk model c, but improvements were much
lower than for type 2 diabetes.
Sensitivity Analyses
Most inflammation-related biomarkers were measured using
high-sensitivity ELISA kits with inter- and intraassay CVs
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generally below 10%, whereas inter- and intraassay CVs for some
parameters measured with bead-based multiplex assays exceeded
10% (Table S1). In order to exclude effects of less robust assays on
the estimation of model accuracy, we repeated our analyses after
exclusion of the four biomarkers that were measured with the
multiplex assay (i.e. IL-18, MCP-1/CCL2, IL-8/CXCL8 and IP-
10/CXCL10). For incident type 2 diabetes, the AUCs for models
b and d were only slightly altered (from 0.801 to 0.796 and from
0.847 to 0.843, respectively). Similar results were seen for incident
coronary events, where the AUCs for models b and d changed
from 0.825 to 0.826 and from 0.851 to 0.852, respectively.
We also performed sensitivity analyses replacing BMI with waist
circumference in our risk models. Unfortunately, waist circumfer-
ence was only measured in S2 und S3, but not in S1. Thus, our
study samples were reduced to 311 cases and 928 non-cases for the
outcome incident type 2 diabetes and to 219 cases and 1,133 non-
cases for the outcome incident coronary events. For type 2
diabetes, the AUCs for models c and d were increased by 0.010
and 0.007, respectively. For coronary events, the increases were
even lower with 0.002 for both models c and d. These results
indicate that the substitution of BMI with waist circumference in
this subpopulation of the case-cohort study only slightly improved
the model accuracy.
Low socioeconomic status represents an important risk factor
for type 2 diabetes and coronary events. Education (in years) is the
only index of socioeconomic status that is available for all
participants of the MONICA/KORA case-cohort study. When
education was added as a covariable to the respective models c
(cardiometabolic risk models), this variable was not significantly
associated with incident type 2 diabetes (P = 0.184) or incident
coronary events (P = 0.859) so that we decided not to include
education in the list of cardiometabolic risk factors.
It has been reported that measures of NRI depend on the chosen
cut-off values [30]. Our initial cut-off values (3%, 8%, 15%) were
based on previous publications [26,27], but at least for incident type
2 diabetes, a clear clinical basis for these cut-off values does not exist.
Therefore, we repeated our analyses with lower (2%, 5%, 10%) and
higher (5%, 10%, 20%) cut-off values. As shown in Table S6, we
found minor changes for NRI values when lower or higher cut-offs
were used, but overall, our results seem relatively robust.
Irrespective of the used cut-off values, NRI values were always
considerably higher for type 2 diabetes than for coronary events.
Figure 1. Hazard ratios (95% CI) for incident type 2 diabetes for z-transformed inflammation-related biomarkers. Solid lines (model 1):
each biomarker adjusted for age, sex and survey. Dashed lines (model 2): each biomarker adjusted for age, sex, survey, BMI, systolic blood pressure,
ratio of total cholesterol to HDL cholesterol, smoking, alcohol consumption, physical activity and parental diabetes.
doi:10.1371/journal.pone.0019852.g001
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Discussion
The main findings of our study are (i) that the combination of 13
biomarkers of subclinical inflammation improved the accuracy of a
risk model of incident type 2 diabetes in the MONICA/KORA
cohort significantly and equally well as a combination of
established cardiometabolic risk factors, (ii) that a combination
of both sets of risk factors led to a further significant improvement
of the accuracy of predicting type 2 diabetes compared with either
set of risk factors alone, and (iii) that the improvement of accuracy
of prediction models for type 2 diabetes over and above age, sex
and cardiometabolic risk factors by the combination of inflam-
mation-related biomarkers was more pronounced than for
coronary events employing the same methods in the same
population.
The study extends previous knowledge because it is the first
study to focus on the predictive value of multiple markers of
subclinical inflammation for incident type 2 diabetes. The set of 13
inflammation-related biomarkers consists of an acute-phase
protein (CRP), cytokines (IL-6, IL-18, TGF-b1, MIF), chemokines
(MCP-1/CCL2, IL-8/CXCL8, IP-10/CXCL10, RANTES/
CCL5), adipokines (adiponectin, leptin) and soluble adhesion
molecules (sE-selectin, sICAM-1) and is therefore more compre-
hensive than the combinations of immune mediators that were
used in the ARIC cohort (leukocyte count, IL-6, four acute-phase
proteins) or the MONICA/KORA cohort (CRP, IL-6, three
chemokines) before [8,9].
Our study design differs in two important aspects from the
design of the aforementioned Inter99 and FINRISK cohorts
[5,10]. First, we provide an estimate of the accuracy of models
based on biomarkers of subclinical inflammation only (over and
above age, sex and survey as essential covariates) and both
compared and combined them with established cardiometabolic
risk factors because we were interested in the contribution of
subclinical inflammation as pathophysiological mechanism to the
development of type 2 diabetes. Therefore, it was not our aim to
build a risk score with optimal predictive value for incident type 2
diabetes. Second, we used nonfasting rather than fasting blood
samples as fasting samples were not available from the MONICA/
KORA Augsburg surveys. Although it could be argued that this
represents a major limitation of our study (to be discussed below),
it should be noted that the question whether inflammation-related
biomarkers from nonfasting samples could be useful in the
prediction of type 2 diabetes has not been addressed in
comparable population-based studies and is therefore of interest.
Although we observed a substantial increase in AUC (0.044
[95% CI 0.028–0.066]) as well as large values for DAIC (139.8),
IDI (0.061) and NRI (0.202) by the addition of inflammation-
related biomarkers to a model that already contained strong
cardiometabolic risk factors for type 2 diabetes, we found that this
increase could be attributed to just a few biomarkers. Only
adiponectin and sE-selectin increased the AUC by more than
0.010 and showed DAIC considerably larger than 10. Importantly,
adiponectin was also one out of four biomarkers (next to
apolipoprotein B, CRP and ferritin) that was included in the final
prediction score derived from 31 biomarkers in the FINRISK97
cohort [5]. Moreover, inclusion of adiponectin in an extensive risk
score based on anthropometric, metabolic and lifestyle factors
led to a small, but significant increase in the AUC in the
Table 1. Predictive value of Cox regression models for each inflammation-related biomarker assessed by AUC for incident type 2
diabetes.
Biomarker AUC1a DAUC1 (95% CI)a AUC2b DAUC2 (95% CI)b
None 0.690 — 0.803 —
hsCRP 0.693 0.003 (0.001–0.008) 0.803 0.000 (20.000–0.002)
IL-6 0.692 0.002 (0.001–0.007) 0.804 0.001 (20.000–0.004)
IL-18 0.694 0.004 (0.002–0.019) 0.805 0.002 (0.000–0.012)
TGF-b1 0.694 0.004 (0.001–0.011) 0.805 0.002 (20.000–0.007)
MIF 0.692 0.002 (0.001–0.007) 0.804 0.001 (20.000–0.003)
MCP-1 0.693 0.003 (0.001–0.010) 0.804 0.001 (20.000–0.006)
IL-8 0.691 0.001 (0.001–0.004) 0.803 0.000 (20.000–0.002)
IP-10 0.695 0.005 (0.001–0.016) 0.807 0.004 (20.000–0.010)
RANTES 0.695 0.005 (0.001–0.013) 0.803 0.000 (20.000–0.003)
Adiponectin 0.753 0.063 (0.042–0.088) 0.826 0.023 (0.010–0.037)
Leptin 0.728 0.038 (0.024–0.062) 0.805 0.002 (20.000–0.007)
sE-selectin 0.716 0.026 (0.010–0.054) 0.821 0.018 (0.006–0.031)
sICAM-1 0.699 0.009 (0.002–0.022) 0.806 0.003 (20.000–0.009)
With all 13 biomarkers 0.801 0.111 (0.092–0.149) 0.847 0.044 (0.028–0.066)
With IL-18, adiponectin, sE-selectin,
sICAM-1c
0.783 0.093 (0.071–0.125) 0.841 0.038 (0.021–0.056)
Bold print denotes statistical significance for DAUC (P,0.05). ‘‘20.000’’ denotes values between 20.0005 and 0.0000.
aAdjusted for age, sex and survey (model 1).
bAdjusted for age, sex, survey, BMI, systolic blood pressure, ratio of total cholesterol/HDL cholesterol, smoking, alcohol, physical activity and parental history of diabetes
(model 2).
cWith biomarkers that were significantly associated with incident type 2 diabetes in multivariable-adjusted models (IL-18, adiponectin, sE-selectin, sICAM-1).
DAUC denotes the differences between the model with the respective inflammation-related biomarker and the model without any inflammation-related biomarker.
DAUC for the difference between the model adjusted for age, sex, survey and cardiometabolic risk factors (model c) and the basic model adjusted for age, sex and
survey (model a) was 0.113 [95% CI 0.093–0.149].
doi:10.1371/journal.pone.0019852.t001
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EPIC-Potsdam Study [31]. We reported before that adiponectin
improved risk prediction over and above cardiometabolic and
selected inflammation-derived biomarkers in the MONICA/
KORA Augsburg case-cohort study [22]. These data are in
contrast with findings from the KORA S4/F4 cohort study, which
was conducted later and independently from the MONICA/
KORA surveys 1–3. In KORA S4/F4, there was no significant
improvement of the AUC when adiponectin was added to a model
that contained HbA1c and fasting glucose [32]. Data on the
impact of sE-selectin on measures of discrimination are available
from a small nested case-control study within the Western New
York Study. The addition of sE-selectin, serum albumin and
leukocyte count improved the accuracy of a risk model for type 2
diabetes compared to a basic model based on sex, BMI and familiy
history of type 2 diabetes [33].
Our findings on type 2 diabetes are in contrast to several other
studies on the improvement by inflammation-related biomarkers
of risk models already containing measure of glycemia or insulin
resistance. In the Insulin Resistance Atherosclerosis Study, the
addition of CRP to a prediction model for type 2 diabetes that was
based on the metabolic syndrome (without or with an estimate of
insulin resistance) had little impact on AUCs [34]. CRP (alone or
in combination with other biomarkers) also failed to improve
AUCs of prediction models already containing plasma glucose
glucose levels as in the Framingham Offspring Study [35] and the
aforementioned EPIC-Potsdam Study [31]. In the Sandy Lake
Health and Diabetes Project, leptin, CRP, IL-6 and serum
amyloid A were included in a risk model based on cardiometabolic
risk factors, adiponectin and impaired glucose tolerance, but could
not improve diabetes prediction [36]. Recently, the Women’s
Health Initiative Observational Study did not find that biomarkers
of subclinical inflammation (hsCRP, IL-6, soluble tumor necrosis
factor-receptor 2) and of endothelial dysfunction (E-selection,
ICAM-1, vascular cell adhesion molecule-1) contribute to the
prediction of incident type 2 diabetes over and above clinical risk
factors and fasting glucose [37]. Taken together, these data suggest
that our findings may be specific for analyses based on nonfasting
blood samples and that the contribution of multiple inflammation-
related biomarkers to prediction models with diabetes risk factors
that are used for the diagnosis of type 2 diabetes (glucose, HbA1c)
may be less pronounced than for prediction models without these
measures of glycemia.
An important aspect of our study is the fact that our case-
cohort design allowed us to compare inflammation-related and
Figure 2. Hazard ratios (95% CI) for incident coronary events for z-transformed inflammation-related biomarkers. Solid lines (model
1): each biomarker adjusted for age, sex and survey. Dashed lines (model 2): each biomarker adjusted for age, sex, survey, BMI, systolic blood
pressure, ratio of total cholesterol to HDL cholesterol, smoking, alcohol consumption, physical activity, parental myocardial infarction and prevalent
diabetes.
doi:10.1371/journal.pone.0019852.g002
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cardiometabolic risk factors for both type 2 diabetes and coronary
events as outcomes using the same methods and two largely
overlapping study populations. The combination of all biomarkers
and risk factors yielded almost identical AUCs for both outcomes.
However, the improvement of inflammation-related biomarkers
over a basic model based on age, sex and survey was considerably
larger for type 2 diabetes (DAUC 0.111 [95% 0.092–0.149]) than
for coronary events (DAUC 0.018 [95% CI 0.013–0.038]). This
difference is confirmed by larger DAIC, IDI and NRI values when
models for both outcomes were compared. This is most likely
attributable to the higher accuracy of the basic model for coronary
events (AUC 0.807) compared to type 2 diabetes (AUC 0.690) so
that further improvements by additional biomarkers or risk factors
can be expected to be less pronounced. Although we found a
significant increase in AUC, these data are in line with data from
other studies that focused on risk models for incident coronary
events or cardiovascular death and that assessed the incremental
predictive value of inflammation-related biomarkers. AUCs for
prediction models based on cardiometabolic factors were usually
in the range between 0.70 and 0.82. Although multiple promising
biomarker candidates were tested, the improvement of risk models
by addition of novel inflammation-related biomarkers was
relatively small, especially when the basic model already had a
good accuracy, and AUCs of the extended models did not increase
beyond 0.82 in these studies [38–45]. A recent study indicated that
in particular N-terminal pro-brain natriuretic peptide (NT-
proBNP) and sensitive troponin I may improve the prediction of
risk of coronary events [44].
Regarding the clinical relevance of our findings, the present
study did not aim at providing a simple clinical risk score, but
rather at studying to which extent subclinical inflammation as one
of several other mechanisms contributes to the prediction of the
development of type 2 diabetes. The approach of this study was
chosen to extend previous work that mainly evaluated statistical
associations between inflammation-related biomarkers and inci-
dent diabetes using Cox regression models.
Overall, our data demonstrate that age (but not sex or survey)
contribute a substantial part to the AUC that can be achieved with
a basic risk model and with more sophisticated models involving
multiple risk factors and biomarkers. Interestingly, although
cardiometabolic risk factors are strongly associated with inflam-
mation-related biomarkers, we found a significant increase in
accuracy when adding inflammation-related biomarkers to a
model based on age, sex and cardiometabolic risk factors.
Therefore, these data are in line with a role for subclinical
inflammation in the development of type 2 diabetes and indicate
that in particular adiponectin and sE-selectin should be further
evaluated as markers for type 2 diabetes risk in combination with
other risk factors and biomarkers.
Strengths of our study include the use of the MONICA/KORA
Augsburg cohort with a large number of cases and non-cases, a
long follow-up period, availability of data for multiple biomarkers
representing different aspects of subclinical inflammation, and the
inclusion of both cases with incident type 2 diabetes and coronary
events in the case-cohort study so that a direct comparison of risk
factors and biomarkers for both outcomes in the same cohort using
the same methods was possible.
There are also several limitations that should be pointed out.
First, we did not perform oral glucose tolerance tests at baseline or
follow-up so that some misclassification may have occurred and
Table 2. Predictive value of Cox regression models for each inflammation-related biomarker assessed by AUC for incident
coronary events.
Biomarker AUC1a DAUC1 (95% CI)a AUC2b DAUC2 (95% CI)b
None 0.807 — 0.845 —
hsCRP 0.809 0.002 (0.001–0.008) 0.845 0.000 (20.001–0.003)
IL-6 0.810 0.003 (0.001–0.008) 0.846 0.001 (20.000–0.004)
IL-18 0.808 0.001 (0.001–0.005) 0.845 0.000 (20.001–0.003)
TGF-b1 0.808 0.001 (0.001–0.005) 0.845 0.000 (20.000–0.003)
MIF 0.809 0.002 (0.001–0.008) 0.845 0.000 (20.000–0.003)
MCP-1 0.808 0.001 (0.001–0.005) 0.845 0.000 (20.001–0.002)
IL-8 0.808 0.001 (0.001–0.003) 0.845 0.000 (20.000–0.002)
IP-10 0.808 0.001 (0.000–0.005) 0.845 0.000 (20.001–0.005)
RANTES 0.808 0.001 (0.001–0.006) 0.845 0.000 (20.000–0.003)
Adiponectin 0.808 0.001 (0.000–0.007) 0.845 0.000 (20.000–0.005)
Leptin 0.811 0.004 (0.001–0.010) 0.845 0.000 (20.000–0.004)
sE-selectin 0.817 0.010 (0.004–0.018) 0.847 0.002 (20.000–0.009)
sICAM-1 0.817 0.010 (0.005–0.021) 0.848 0.003 (0.000–0.011)
With all 13 biomarkers 0.825 0.018 (0.013–0.038) 0.851 0.006 (0.003–0.021)
With IL-6,sICAM-1c 0.819 0.012 (0.006–0.024) 0.849 0.004 (0.001–0.012)
Bold print denotes statistical significance for DAUC (P,0.05). ‘‘20.000’’ denotes values between 20.0005 and 0.0000.
aAdjusted for age, sex and survey (model 1).
bAdjusted for age, sex, survey, BMI, systolic blood pressure, ratio of total cholesterol/HDL cholesterol, smoking, alcohol, physical activity, parental myocardial infarction
and prevalent diabetes (model 2).
cWith biomarkers that were significantly associated with incident coronary events in multivariable-adjusted models (IL-6, sICAM-1).
DAUC denotes the differences between the model with the respective inflammation-related biomarker and the model without any inflammation-related biomarker.
DAUC for the difference between the model adjusted for age, sex, survey and cardiometabolic risk factors (model c) and the basic model adjusted for age, sex and
survey (model a) was 0.038 [95% CI 0.026–0.055].
doi:10.1371/journal.pone.0019852.t002
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the outcome of our study was physician-diagnosed type 2 diabetes.
Second, we had no data on fasting glucose and fasting insulin
(HbA1c data for a subgroup of study participants only) so that we
could not investigate the change in AUC by inflammation-related
biomarkers over a model that contained these variables. In
addition, minor variations of levels of inflammation-related
biomarkers due to the nonfasting state cannot be excluded. Third,
we used continuous values of biomarker concentrations in order to
render results comparable to other studes [5,44], although
consideration of sex differences or non-linear associations between
biomarkers and endpoints could have led to higher accuracy of our
models. Fourth, biomarkers of non-alcoholic fatty liver disease
(liver enzymes such as alanine aminotransferase, aspartate
aminotransferase or c-glutamyl transferase) are relevant risk
factors for type 2 diabetes [4,46], but were not available in our
study (with the exception of c-glutamyl transferase in S1) so that
we could not include them in our cardiometabolic risk models.
Finally, we did not seek for external replication of our results.
Taken together, 13 inflammation-related biomarkers measured
in nonfasting serum samples significantly improved the prediction
of incident type 2 diabetes and coronary events over and above
cardiometabolic risk factors in the MONICA/KORA study, but
this improvement was much more pronounced for type 2 diabetes.
Our study could not address the question whether biomarkers of
subclinical inflammation can also improve the predictive value of
risk models that contain various measures of glycemia. Therefore,
further research is warranted to investigate whether multiple
inflammation-related biomarkers can increase the accuracy of risk
models that include data on (fasting or nonfasting) glucose, insulin
or HbA1c levels.
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Diabetes Center, Düsseldorf) and Gerlinde Trischler (University of Ulm)
for excellent technical assistance and Andrea Schneider (Helmholtz
Zentrum München) for excellent data management. Finally, we express
our appreciation to all study participants.
Author Contributions
Conceived and designed the experiments: CH WK BT. Performed the
experiments: CH MR CM MK AP WK BT. Analyzed the data: CH JB AZ
LC WR BT. Wrote the paper: CH. Commented on the manuscript with
important intellectual contributions: JB AZ MR CM MK LC WR AP WK
BT.
References
1. Kolb H, Mandrup-Poulsen T (2005) An immune origin of type 2 diabetes?
Diabetologia 48: 1038–1050.
2. Larsen CM, Faulenbach M, Vaag A, Vølund A, Ehses JA, et al. (2007)
Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 356:
1517–1526.
3. Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, et al. (2010) The
effects of salsalate on glycemic control in patients with type 2 diabetes: a
randomized trial. Ann Intern Med 152: 346–357.
4. Sattar N, Wannamethee SG, Forouhi NG (2008) Novel biochemical risk factors
for type 2 diabetes: pathogenic insights or prediction possibilities? Diabetologia
51: 926–940.
5. Salomaa V, Havulinna A, Saarela O, Zeller T, Jousilahti P, et al. (2010) Thirty-
one novel biomarkers as predictors for clinically incident diabetes. PLoS ONE
5(4): e10100.
6. Pepe MS, Janes H, Longton G, Leisenring W, Newcomb P (2004) Limitations of
the odds ratio in gauging the performance of a diagnostic, prognostic, or
screening marker. Am J Epidemiol 159: 882–890.
7. Janssens ACJW, Aulchenko YS, Elefante S, Borsboom GJJM, Steyerberg EW,
et al. (2006) Predictive testing for complex diseases using multiple genes: fact or
fiction? Genet Med 8: 395–400.
8. Duncan BB, Schmidt MI, Pankow JS, Ballantyne CM, Couper D, et al. (2003)
Low-grade systemic inflammation and the development of type 2 diabetes:
the Atherosclerosis Risk in Communities Study. Diabetes 52: 1799–
1805.
9. Herder C, Baumert J, Thorand B, Koenig W, de Jager W, et al. (2006)
Chemokines as risk factors for type 2 diabetes: results from the MONICA/
KORA Augsburg Study, 1984–2002. Diabetologia 49: 921–929.
10. Kolberg JA, Jorgensen T, Gerwien RW, Hamren S, McKenna MP, et al. (2009)
Development of a type 2 diabetes risk model from a panel of serum biomarkers
from the Inter99 cohort. Diabetes Care 32: 1207–1212.
11. Petrovsky N, Socha L, Silva D, Grossman AB, Metz C, et al. (2003) Macrophage
migration inhibitory factor exhibits a pronounced circadian rhythm relevant to
its role as a glucocorticoid counter-regulator. Immunol Cell Biol 81: 137–143.
12. Esposito K, Nappo F, Giugliano F, Di Palo C, Ciotola M, et al. (2003) Meal
modulation of circulating interleukin 18 and adiponectin concentrations in
healthy subjects and in patients with type 2 diabetes mellitus. Am J Clin Nutr 78:
1135–1140.
13. Thorand B, Kolb H, Baumert J, Koenig W, Chambless L, et al. (2005) Elevated
levels of interleukin-18 predict the development of type 2 diabetes: results from
the MONICA/KORA Augsburg Study 1984–2002. Diabetes 54: 2932–2938.
14. Herder C, Klopp N, Baumert J, Müller M, Khuseyinova N, et al. (2008) Effect of
macrophage migration inhibitory factor (MIF) gene variants and MIF serum
concentrations on the risk of type 2 diabetes: results from the MONICA/KORA
Augsburg Case-Cohort Study, 1984–2002. Diabetologia 51: 276–284.
15. Alpert JS, Thygesen K, Antman E, Bassand JP (2000) Myocardial infarction
redefined: a consensus document of The Joint European Society of Cardiology/
American College of Cardiology Committee for the redefinition of myocardial
infarction. J Am Coll Cardiol 36: 959–969.
Immunological Risk Factors and Type 2 Diabetes
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e19852
16. Luepker RV, Apple FS, Christenson RH, Crow RS, Fortmann SP, et al. (2003)
Case definitions for acute coronary heart disease in epidemiology and clinical
research studies: a statement from the AHA Council on Epidemiology and
Prevention; AHA Statistics Committee; World Heart Federation Council on
Epidemiology and Prevention; the European Society of Cardiology Working
Group on Epidemiology and Prevention; Centers for Disease Control and
Prevention; and the National Heart, Lung, and Blood Institute. Circulation 108:
2543–2549.
17. Schaeffler V, Döring A, Winkler G, Keil U (1996) Trends in food consumption
in a south German population from 1984/85 to 1989/90: results from the WHO
MONICA project Augsburg. Ann Nutr Metab 40: 129–136.
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